基本數據
| CIK | 1075880 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Novogen Ltd.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| June 2, 2026 |
10,700,211 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-292303 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 10,700,211 American Depositary Shares representing 5,350,105,500 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a |
|
| June 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2026 Commission File Number: 000-29962 Kazia Therapeutics Limited. (Exact Name of Registrant as Specified in Its Charter) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| June 2, 2026 |
95,110 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part of |
|
| June 2, 2026 |
Offer of Employment with Kazia Therapeutics Exhibit 10.1 June 1, 2026 James Levine San Diego, CA Dear James, Offer of Employment with Kazia Therapeutics On behalf of Kazia Therapeutics, Inc, I am pleased to offer you the position of Chief Financial Officer. We look forward to welcoming you as a colleague. The terms of the position are as set forth below. Position Particulars. Your position, place of work, and commencement date will be as de |
|
| June 2, 2026 |
266,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part |
|
| June 2, 2026 |
232,956 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-290598 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a part |
|
| June 2, 2026 |
Kazia Therapeutics Appoints James Levine as Chief Financial Officer Exhibit 99.1 Kazia Therapeutics Appoints James Levine as Chief Financial Officer SYDNEY, Australia, June 2, 2026 – Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia,” “Kazia Therapeutics” or the “Company”), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of James Levine as Chief Financial |
|
| May 26, 2026 |
232,956 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-290598 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a part |
|
| May 26, 2026 |
95,110 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part of |
|
| May 26, 2026 |
266,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part |
|
| May 26, 2026 |
Exhibit 99.1 Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, Australia, May 26, 2026 – Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), a clinical-stage oncology company advancing therapies designed to reprogram can |
|
| May 26, 2026 |
10,700,211 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-292303 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 10,700,211 American Depositary Shares representing 5,350,105,500 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a |
|
| May 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 000-29962 Kazia Therapeutics Limited. (Exact Name of Registrant as Specified in Its Charter) Three International Towers Level 24 300 Barangaroo Avenue Sydney NS |
|
| April 27, 2026 |
Exhibit 99.1 NASDAQ: KZIA | X: @KaziaTx Beyond Inhibition. Reprogramming Cancer Control. 2026 Corporate Overview April 2026 This presentation contains forward - looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar words. Any statement describi |
|
| April 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 000-29962 Kazia Therapeutics Limited. (Exact Name of Registrant as Specified in Its Charter) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| April 27, 2026 |
Exhibit 99.2 Financial Insights Cash & Cash Equivalents: ~ US$46 million (Runway expected to fund planned operations into 2029, excluding additional or expanded trials) Debt: No outstanding debt Ticker: KZIA (NASDAQ) American Depository Shares Outstanding: ~ 11.4 million Key Investment Highlights Portfolio: o Paxalisib , a brain - penetrant, oral, small molecule dual PI3K / mTOR inhibitor with epi |
|
| April 15, 2026 |
10,700,211 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-292303 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 10,700,211 American Depositary Shares representing 5,350,105,500 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a |
|
| April 15, 2026 |
232,956 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-290598 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a part |
|
| April 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 000-29962 Kazia Therapeutics Limited. (Exact Name of Registrant as Specified in Its Charter) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| April 15, 2026 |
95,110 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part of |
|
| April 15, 2026 |
Offer of Employment with Kazia Therapeutics Limited Exhibit 10.1 February 23, 2026 Dr Sudha Rao 14 Captains Court, Raby Bay Cleveland QLD 4164 Dear Sudha, Offer of Employment with Kazia Therapeutics Limited On behalf of Kazia Therapeutics Limited, I am pleased to offer you the position of Chief Scientific Officer. We look forward to welcoming you as a colleague. The terms of the position are as set forth below. Position Particulars. Your position, |
|
| April 15, 2026 |
Exhibit 99.1 Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform Sydney, Australia – April 15, 2026 – Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Ch |
|
| April 15, 2026 |
266,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part |
|
| April 13, 2026 |
95,110 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part of |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 000-29962 Kazia Therapeutics Limited. (Exact Name of Registrant as Specified in Its Charter) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| April 13, 2026 |
Exhibit 99.1 Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform Sydney, Australia – April 13, 2026 – Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug dev |
|
| April 13, 2026 |
266,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part |
|
| April 13, 2026 |
10,700,211 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-292303 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 10,700,211 American Depositary Shares representing 5,350,105,500 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a |
|
| April 13, 2026 |
232,956 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-290598 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a part |
|
| April 1, 2026 |
266,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part |
|
| April 1, 2026 |
95,110 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part of |
|
| April 1, 2026 |
232,956 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-290598 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a part |
|
| April 1, 2026 |
10,700,211 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-292303 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 10,700,211 American Depositary Shares representing 5,350,105,500 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 000-29962 Kazia Therapeutics Limited. (Exact Name of Registrant as Specified in Its Charter) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| March 31, 2026 |
Exhibit 99.2 Kazia Therapeutics Limited ("Kazia") is a Sydney-based clinical-stage oncology company focused on high- need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redef |
|
| March 31, 2026 |
Exhibit 99.1 NASDAQ: KZIA | X: @KaziaTx Beyond Inhibition. Reprogramming Cancer Control. 2026 Corporate Overview March 2026 1 This presentation contains forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," "plan," "expect," "explore," "potential" or other similar words. Any statement describi |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 000-29962 Kazia Therapeutics Limited. (Exact Name of Registrant as Specified in Its Charter) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| March 30, 2026 |
Exhibit 99.1 Kazia Therapeutics Limited ABN 37 063 259 754 Half Yearly Report - 31 December 2025 Kazia Therapeutics Limited Directors’ report 31 December 2025 The directors present their report, together with the financial statements, on the Consolidated entity (referred to hereafter as the ‘Consolidated entity’) consisting of Kazia Therapeutics Limited (referred to hereafter as the ‘Consolidated |
|
| March 26, 2026 |
March 26, 2026 Securities and Exchange Commission 100 F. Street, NE Washington, D.C. 20549 Re: Kazia Therapeutics Ltd. (“Company”) Registration Statement on Form F-3 File No. 333-294392 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Kazia Therapeutics Limited (the “Company”) hereby requests that the effective date of the above-referen |
|
| March 25, 2026 |
March 25, 2026 John Friend Chief Executive Officer Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re: Kazia Therapeutics Limited Registration Statement on Form F-3 Filed March 18, 2026 File No. |
|
| March 19, 2026 |
Exhibit 99.1 Kazia Therapeutics Limited ABN 37 063 259 754 Half Yearly Report - 31 December 2025 Kazia Therapeutics Limited Directors’ report 31 December 2025 The directors present their report, together with the financial statements, on the Consolidated entity (referred to hereafter as the ‘Consolidated entity’) consisting of Kazia Therapeutics Limited (referred to hereafter as the ‘Consolidated |
|
| March 19, 2026 |
10,700,211 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-292303 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 10,700,211 American Depositary Shares representing 5,350,105,500 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which fo |
|
| March 19, 2026 |
95,110 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a p |
|
| March 19, 2026 |
232,956 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-290598 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March , 2026 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 200 |
|
| March 19, 2026 |
266,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a |
|
| March 18, 2026 |
Exhibit 1.2 KAZIA THERAPEUTICS LTD. American Depositary Shares each representing 500 fully paid Ordinary Shares SALES AGREEMENT March 17, 2026 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Kazia Therapeutics Limited ACN 063 259 754, an Australian public company limited by shares (the “Company”), confirms its agreement (this “Agreement”) |
|
| March 18, 2026 |
As filed with the Securities and Exchange Commission on March 17, 2026. As filed with the Securities and Exchange Commission on March 17, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kazia Therapeutics Limited (Exact name of registrant as specified in its charter) Not Applicable (Translation of registrant’s name into English) Australia 2834 Not Appli |
|
| March 18, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 KAZIA THERAPEUTICS LTD Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, no par value per share, in the form of American Depositary Shares (1) 457(o) $ $ 0. |
|
| January 27, 2026 |
10,700,211 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-292303 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 10,700,211 American Depositary Shares representing 5,350,105,500 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which fo |
|
| January 27, 2026 |
95,110 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a p |
|
| January 27, 2026 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NS |
|
| January 27, 2026 |
266,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated December 22, 2025) 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a |
|
| January 27, 2026 |
EX-99.1 Exhibit 99.1 Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Sydney, Australia, January 27, 2026; Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in pat |
|
| January 27, 2026 |
232,956 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-290598 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2025) 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a |
|
| December 23, 2025 |
424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-292303 PROSPECTUS 10,700,211 American Depositary Shares Representing 5,350,105,500 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholders named in this prospectus (the “Selling Shareholders”) from time to time of up to an aggregate of 10,700,211 American Depositary Sh |
|
| December 23, 2025 |
424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-290598 PROSPECTUS 232,956 American Depositary Shares Representing 116,478,000 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholders named in this prospectus (the “Selling Shareholders”) from time to time of up to an aggregate of 232,956 American Depositary Shares (th |
|
| December 23, 2025 |
95,110 American Depositary Shares Representing 47,555,000 Ordinary Shares Kazia Therapeutics Limited 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS 95,110 American Depositary Shares Representing 47,555,000 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 95,110 American Depositary Shares, or the Offered ADSs, with each Ame |
|
| December 23, 2025 |
424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS 266,666 American Depositary Shares Representing 133,333,000 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholder named in this prospectus from time to time of up to an aggregate of 266,666 American Depositary Shares, or the January 2025 Offered ADSs |
|
| December 22, 2025 |
CORRESP December 22, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 22, 2025 |
CORRESP December 22, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 19, 2025 |
As filed with the Securities and Exchange Commission on December 19, 2025 POS AM Table of Contents As filed with the Securities and Exchange Commission on December 19, 2025 Registration No. |
|
| December 19, 2025 |
As filed with the Securities and Exchange Commission on December 19, 2025 F-1/A Table of Contents As filed with the Securities and Exchange Commission on December 19, 2025 Registration No. |
|
| December 19, 2025 |
As filed with the Securities and Exchange Commission on December 19, 2025 POS AM Table of Contents As filed with the Securities and Exchange Commission on December 19, 2025 Registration No. |
|
| December 19, 2025 |
Calculation of Filing Fee Tables F-1 KAZIA THERAPEUTICS LTD Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Ordinary shares, no nominal value per share 457(a) 5,350,105,500 $ 0. |
|
| December 19, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| December 19, 2025 |
As filed with the Securities and Exchange Commission on December 19, 2025 F-1 Table of Contents As filed with the Securities and Exchange Commission on December 19, 2025 Registration No. |
|
| December 10, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| December 10, 2025 |
EX-99.1 Exhibit 99.1 Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib’s Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters Reinvigoration of |
|
| December 5, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| December 2, 2025 |
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities EX-99.1 Exhibit 99.1 Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities Sydney, Australia / PRNewswire / December 2, 2025 / Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a pr |
|
| December 2, 2025 |
AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES KAZIA THERAPEUTICS LIMITED EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PUR |
|
| December 2, 2025 |
EX-10.2 Exhibit 10.2 PLACEMENT AGENCY AGREEMENT December 2, 2025 Konik Capital Partners LLC, a division of T.R. Winston & Company 7 World Trade Center, 46th Floor New York, NY 10007 Ladies and Gentlemen: This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which Konik Capital Partners LLC, a division of T.R. Winston & Company (the “Placement Agent”), shall be engaged by Kazi |
|
| December 2, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| December 2, 2025 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PUR |
|
| December 2, 2025 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of December 2, 2025, is between Kazia Therapeutics Limited ACN 063 259 754, a company incorporated under the laws of the Commonwealth of Australia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” an |
|
| November 18, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| November 18, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| November 18, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| November 18, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| November 7, 2025 |
EX-4.22 Exhibit 4.22 This Asset Transfer Agreement (the “Agreement”) is made effective as of March 30, 2025 (the “Effective Date”) by and between (1) Vivesto AB (publ), Box 3061 169 03 Solna, Sweden, Sweden (“Vivesto”) and (2) Kazia Therapeutics Limited (ACN 063 259 754) of Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000, Australia (“Kazia”). Recitals (A) Kazia exclusi |
|
| November 7, 2025 |
EX-15.1 Exhibit 15.1 Tel: +61 2 9251 4100 Fax: +61 2 9240 9821 www.bdo.com.au Parkline Place Level 25, 252 Pitt Street Sydney NSW 2000 Australia CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (No. 333-281937 and 333-276091) of Kazia Therapeutics Limited (the Company) of our report dated November |
|
| November 7, 2025 |
EX-4.23 Exhibit 4.23 Confidential Certain information identified by [***] has been omitted from this exhibit because it is both not material and is the type that the registrant treats as confidential LICENSE AND COMMERCIALISATION AGREEMENT This LICENSE AND COMMERCIALISATION AGREEMENT (this Agreement”) is made as of 3 October, 2025 (“Effective Date”), by and between KAZIA THERAPEUTICS LIMITED ABN 3 |
|
| November 7, 2025 |
EX-12.1 Exhibit 12.1 Certification of the Principal Executive Officer as required by Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, John Friend, certify that: 1. I have reviewed this Annual Report on Form 20-F for the fiscal year ended June 30, 2025 (“Report”) of Kazia Therapeutics Limited (the “Company”); 2. Based on my knowledge, this Report does not contain any untrue statement of |
|
| November 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
| November 7, 2025 |
EX-13.1 Exhibit 13.1 Certification of the Principal Executive Officer and the Principal Financial Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), John Fri |
|
| November 7, 2025 |
EX-12.2 Exhibit 12.2 Certification of the Principal Financial Officer as required by Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jeffrey Bonacorda, certify that: 1. I have reviewed this Annual Report on Form 20-F for the fiscal year ended June 30, 2025 (“Report”) of Kazia Therapeutics Limited (the “Company”); 2. Based on my knowledge, this Report does not contain any untrue statem |
|
| October 31, 2025 |
NT 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transitio |
|
| October 7, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| October 7, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| October 7, 2025 |
EX-99.1 Exhibit 99.1 Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program Sydney, Australia – October 7, 2025 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the “Agreement”) with QIMR Berghofer for a first-in-class PD- |
|
| October 7, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NS |
|
| October 7, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| October 2, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| October 2, 2025 |
EX-99.1 Exhibit 99.1 Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen Sydney, Australia – October 2, 2025; Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today reported a substantial reduction in tumor burden from a single-patient expanded access case |
|
| October 2, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| October 2, 2025 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydn |
|
| October 2, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| September 30, 2025 |
Calculation of Filing Fee Tables F-1 KAZIA THERAPEUTICS LTD Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Ordinary shares, no nominal value per share 457(a) 116,478,000 $ 0. |
|
| September 30, 2025 |
As filed with the Securities and Exchange Commission on September 30, 2025 F-1 Table of Contents As filed with the Securities and Exchange Commission on September 30, 2025 Registration No. |
|
| September 11, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| September 11, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| September 11, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| September 11, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| September 11, 2025 |
EX-99.1 Exhibit 99.1 Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy Sydney, Australia – September 11, 2025 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Su |
|
| August 1, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW |
|
| August 1, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| August 1, 2025 |
EX-4.1 Exhibit 4.1 PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES KAZIA THERAPEUTICS LIMITED Number of Ordinary Shares: , represented by American Depositary Shares Issue Date: August, 2025 THIS PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Hold |
|
| August 1, 2025 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of July 31, 2025, is between Kazia Therapeutics Limited, a company incorporated under the laws of Australia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHERE |
|
| August 1, 2025 |
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market EX-99.1 Exhibit 99.1 Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market SYDNEY, August 1, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIPE). Pursuant to |
|
| August 1, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| August 1, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| July 25, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| July 25, 2025 |
Up to $1,906,196 American Depositary Shares representing Ordinary Shares 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-281937 PROSPECTUS SUPPLEMENT (to Prospectus dated September 12, 2024) Up to $1,906,196 American Depositary Shares representing Ordinary Shares We have entered into an At The Market Offering Agreement, or the Sales Agreement, with Rodman & Renshaw LLC, or Rodman & Renshaw, dated July 25, 2025, relating to the sale of Amer |
|
| July 25, 2025 |
AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT July 25, 2025 Rodman & Renshaw LLC 600 Lexington Avenue, 32nd Floor New York, NY 10022 Ladies and Gentlemen: Kazia Therapeutics Limited ACN 063 259 754, an Australian public company limited by shares (the “Company”), confirms its agreement (this “Agreement”) with Rodman & Renshaw LLC and its successors and permitted assigns (the “Manager”) as follows: 1 |
|
| July 25, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| July 25, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| July 9, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| July 9, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| July 9, 2025 |
Exhibit 99.1 Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizuma |
|
| July 9, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part of |
|
| June 11, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| June 11, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| June 11, 2025 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| June 11, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| June 11, 2025 |
Exhibit 99.1 Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib’s Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) Sydney, Australia – 11 June 2025 – Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publication of transformat |
|
| June 10, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part of |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June , 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| June 10, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| June 10, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| June 10, 2025 |
Exhibit 99.1 Kazia Therapeutics Limited ABN 37 063 259 754 Half Yearly Report - 31 December 2024 Kazia Therapeutics Limited Directors’ report 31 December 2024 The directors present their report, together with the financial statements, on the Consolidated entity (referred to hereafter as the ‘Consolidated entity’) consisting of Kazia Therapeutics Limited (referred to hereafter as the ‘Consolidated |
|
| June 5, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part |
|
| June 5, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| June 5, 2025 |
6-K 1 d832779d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Bara |
|
| June 5, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| June 5, 2025 |
EX-99.1 2 d832779dex991.htm EX-99.1 Exhibit 99.1 Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve patient outcomes in advanced breast cancer Sydney, Australia – June 5, 2025. Kazia T |
|
| May 28, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| May 28, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| May 28, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part of |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 ( |
|
| May 15, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| May 15, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| May 15, 2025 |
Exhibit 99.1 15 May 2025 Kazia Therapeutics Highlights Recent Progress and Provides Business Update Awarded research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson’s disease (PD) Launched clinical trial ev |
|
| May 15, 2025 |
FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| May 15, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part of |
|
| April 15, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 1,373,333 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part |
|
| April 15, 2025 |
FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| April 15, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| April 15, 2025 |
475,555 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a pa |
|
| March 31, 2025 |
Exhibit 99.1 31 March 2025 Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil Sydney, March 31, 2025 – Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or “the Company”), an oncology-focused drug development c |
|
| March 31, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| March 31, 2025 |
475,555 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| March 31, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 1,373,333 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part |
|
| March 13, 2025 |
Exhibit 99.1 Exhibit 99.1 2024 ANNUAL REPORT Contents 2 4 6 Chairman and Key About GBM CEO’s Letter Milestones 8 12 Environment, Financial Society & Reports Governance ii ASX:KZA | NASDAQ:KZIA Chairman and CEO’s The journey of a young biotech Letter company is often circuitous, but we have nevertheless continued to make great progress in the past year. We Key have two first-class drug candidates M |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| February 21, 2025 |
424B3 1 d910443d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 1,373,333 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “P |
|
| February 20, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| February 20, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| February 20, 2025 |
Exhibit 99.1 20 February 2025 Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson’s Disease Sydney, February 20, 2025 – Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or “the Company”), an oncology-focused drug development company, today announced a research |
|
| February 20, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| February 5, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS 1,373,333 American Depositary Shares Representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 1,373,333 American Depositary Shares, or the Offered ADSs, with each Am |
|
| February 3, 2025 |
CORRESP 1 filename1.htm February 3, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Kazia Therapeutics Limited Acceleration Request for Registration Statement on Form F-1 File No. 333-284606 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), K |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| February 3, 2025 |
Exhibit 99.1 A Diversified Oncology Drug Development Company Kazia Corporate Overview January 2025 NASDAQ: KZIA | X: @KaziaTx Forward Looking Statements This presentation contains forward -looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar w |
|
| January 31, 2025 |
January 31, 2025 John Friend Chief Executive Officer and Director Kazia Therapeutics Limited Three International Towers Level 24 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re: Kazia Therapeutics Limited Registration Statement on Form F-1 Filed January 30, 2025 File No. |
|
| January 30, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NS |
|
| January 30, 2025 |
EX-99.1 Exhibit 99.1 Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Sydney; 30 January 2025: Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxali |
|
| January 30, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| January 30, 2025 |
As filed with the Securities and Exchange Commission on January 30, 2025 F-1 Table of Contents As filed with the Securities and Exchange Commission on January 30, 2025 Registration No. |
|
| January 30, 2025 |
EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form F-1 (Form Type) Kazia Therapeutics Limited (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, no nominal value per share(1) Rule 457(c) 137,333,300 $0. |
|
| January 30, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| January 16, 2025 |
Exhibit 1 AGREEMENT OF JOINT FILING The undersigned hereby agree that they are filing jointly, pursuant to Rule 13d-1 of the Securities Exchange Act of 1934, the Schedule 13G dated on or about January 16, 2025, containing the information required by Schedule 13G, for the American Depositary Shares of Kazia Therapeutics Limited held by Alumni Capital LP, a Delaware limited partnership, and with respect to Alumni Capital GP LLC, the manager of Alumni Capital, and Ashkan Mapar, the manager of Alumni Capital GP LLC, such other holdings as may be reported therein. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| January 13, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| January 13, 2025 |
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering Exhibit 99.1 Kazia Therapeutics Announces $2.0 Million Registered Direct Offering SYDNEY, Australia, January 10, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused drug development company, today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the Company’s American Depositary Sh |
|
| January 13, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of January 10, 2025, is between Kazia Therapeutics Limited, a company incorporated under the laws of Australia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, s |
|
| January 13, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281937 PROSPECTUS SUPPLEMENT (To prospectus dated September 12, 2024) 553,440 American Depositary Shares representing 55,344,000 Ordinary Shares Pre-funded Warrants to Purchase up to 779,893 American Depositary Shares Up to 779,893 American Depositary Shares representing 77,989,300 Ordinary Shares issuable upon exercise of the |
|
| January 13, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T |
|
| January 13, 2025 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT January 10, 2025 Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Dear Mr. Friend: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Kazia Therapeutics Limited, a company organized in Australia (the “Company”), pursuant to wh |
|
| January 13, 2025 |
Exhibit 4.1 PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES KAZIA THERAPEUTICS LIMITED Number of American Depositary Shares: Issue Date: , 2025 THIS PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subje |
|
| January 13, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| January 13, 2025 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T |
|
| January 13, 2025 |
Exhibit 4.4 LOCK-UP AGREEMENT January 10, 2025 Re: Securities Purchase Agreement, dated as of January 10, 2025, between Kazia Therapeutics Limited (the “Company”) and the purchasers signatory thereto (the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set forth in the Securities Purchase Agreement (t |
|
| January 10, 2025 |
Kazia Therapeutics Limited Up to $1,734,081 American Depositary Shares representing Ordinary Shares PROSPECTUS SUPPLEMENT (to Prospectus Supplement dated September 12, 2024 and Prospectus dated September 12, 2024) Filed pursuant to Rule 424(b)(5) Registration No. |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| December 31, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| December 31, 2024 |
8,850,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| December 31, 2024 |
Exhibit 99.1 31 December 2024 Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA Sydney, December 31, 2024–Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| December 11, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| December 11, 2024 |
EX-99.1 Exhibit 99.1 11 December 2024 Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium Sydney, December 11, 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development, announced that data from two abstracts wil |
|
| December 11, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| December 3, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS Up to 7,500,000 American Depositary Shares Representing 750,000,000 Ordinary Shares Warrant to Purchase Up to 1,350,000 American Depositary Shares Up to 1,350,000 American Depositary Shares Representing 135,000,000 Ordinary Shares Issuable Upon Exercise of the Warrant Kazia Therapeutics Limited This prospectu |
|
| December 3, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS 475,555 American Depositary Shares representing 47,555,500 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 475,555 American Depositary Shares, or the Offered ADSs, with each America |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 Table of Contents As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 Table of Contents As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 15, 2024 |
DESCRIPTION OF AMERICAN DEPOSITARY SHARES Exhibit 2.2 DESCRIPTION OF AMERICAN DEPOSITARY SHARES The Bank of New York Mellon, as depositary, has registered and delivered American Depositary Shares, also referred to as ADSs. Each ADS represents 100 ordinary shares (or a right to receive 100 ordinary shares) deposited with HSBC Bank Australia Limited, as custodian for the depositary. Each ADS may also represent any other securities, cash or |
|
| November 15, 2024 |
EX-12.1 Exhibit 12.1 Certification of the Principal Executive Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, John Friend, certify that: 1. I have reviewed this Annual Report on Form 20-F for the fiscal year ended June 30, 2024 (“Report”) of Kazia Therapeutics Limited (the “Company”); 2. Based on my knowledge, this Report does not contain any untrue statement of a m |
|
| November 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
| November 15, 2024 |
Exhibit 11.1 Securities Trading Policy Kazia Therapeutics Limited (ACN 063 259 754) (Company) Approved by the Board on 24 February 2021 Table of contents 1. Purpose 3 2. Insider trading prohibitions in the Corporations Act 4 3. No dealing in Prohibited Periods 6 4. Exceptional circumstances 8 5. Permitted dealings 9 6. Further restrictions 11 7. Confidential Information 12 8. Review and publicatio |
|
| November 15, 2024 |
Offer of Employment with Kazia Therapeutics Exhibit 4.21 April 25, 2024 Jeffrey Bonacorda [***] Dear Jeff, Offer of Employment with Kazia Therapeutics On behalf of Kazia Therapeutics, Inc, I am pleased to offer you the position of Vice President Finance and Controller. We look forward to welcoming you as a colleague. The terms of the position are as set forth below. Position Particulars. Your position, place of work, and commencement date w |
|
| November 15, 2024 |
EX-13.1 Exhibit 13.1 Certification of the Principal Executive Officer and the Principal Financial Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), John Fri |
|
| November 15, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated October 14, 2022 with respect to the consolidated financial statements included in the Annual Report of Kazia Therapeutics Limited on Form 20-F, prior to the restatement due to the correction of an error, as described in Note 4, and a reclassification as described in Note 5, for the year ended Jun |
|
| November 15, 2024 |
EX-12.2 Exhibit 12.2 Certification of the Principal Financial Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Jeffrey Bonacorda, certify that: 1. I have reviewed this Annual Report on Form 20-F for the fiscal year ended June 30, 2024 (“Report”) of Kazia Therapeutics Limited (the “Company”); 2. Based on my knowledge, this Report does not contain any untrue statement |
|
| November 15, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-281937 and 333-276091) of Kazia Therapeutics Limited (the Company) of our report dated November 15, 2024, relating to the consolidated financial statements which appears in this Annual Report on Form 20-F. Our report contains |
|
| November 15, 2024 |
KAZIA THERAPEUTICS LIMITED COMPENSATION RECOVERY POLICY Adopted as of October 24, 2023 Exhibit 97.1 KAZIA THERAPEUTICS LIMITED COMPENSATION RECOVERY POLICY Adopted as of October 24, 2023 Kazia Therapeutics Limited, a public company under the Australian Corporations Act 2001 (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| November 12, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| November 12, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| November 12, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| November 6, 2024 |
SC 13G 1 KaziaTherapeutics21.txt SC 13G Schedule 13G Name of issuer: Kazia Therapeutics Ltd Title of class of securities: Sponsored ADR Cusip: 48669G105 Date of event which requires filing: 09/30/2024 Rule 13d-1(b) 1. Platinum Investment Management Limited 2. (b) 3. 4. Sydney Australia 5. Platinum Investment Management Limited 0 (0%) Note:Combined total of underlying managed funds 6. N/A 7. Platin |
|
| November 4, 2024 |
Exhibit 99.1 4 November 2024 Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM) Company updates to corporate presentation and participation in upcoming |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| November 4, 2024 |
Exhibit 99.2 A Diversified Oncology Drug Development Company Kazia Corporate Overview November 2024 NASDAQ: KZIA | X: @KaziaTx Forward Looking Statements This presentation contains forward -looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report |
|
| October 24, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| October 24, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW |
|
| October 24, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| October 15, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| October 15, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| October 15, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| October 2, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| October 2, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| October 2, 2024 |
Exhibit 99.1 2 October 2024 Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66thAnnual Meeting Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial resp |
|
| October 2, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| September 23, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| September 23, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| September 23, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| September 23, 2024 |
EX-99.1 Exhibit 99.1 23 September 2024 Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium Sydney, September 23, 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) |
|
| September 23, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| September 13, 2024 |
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER EX-99.1 Exhibit 99.1 12 September 2024 KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER Sydney, September 12, 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia’s foremost cancer research centres, to obtain an exclusive licen |
|
| September 13, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| September 13, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| September 13, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| September 13, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| September 10, 2024 |
September 10, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 9, 2024 |
September 9, 2024 John Friend Chief Executive Officer Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re: Kazia Therapeutics Limited Registration Statement on Form F-3 Filed September 5, 2024 File No. |
|
| September 5, 2024 |
AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT September 4, 2024 Exhibit 1.3 AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT September 4, 2024 This Amendment No. 1 (“Amendment No. 1”) amends that certain Equity Distribution Agreement, dated April 22, 2022 (the “Agreement”), by and between Kazia Therapeutics Limited ACN 063 259 754 (the “Company”) and Oppenheimer & Co. Inc., as sales agent (the “Sales Agent”). Defined terms used herein and not otherwise defined |
|
| September 5, 2024 |
As filed with the Securities and Exchange Commission on September 4, 2024. F-3 Table of Contents As filed with the Securities and Exchange Commission on September 4, 2024. |
|
| September 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Kazia Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Primary Offering of Securities: Fees to Be Paid Equity Ordinary Shares, par value $0. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kazia Therapeutics Limited (Name of Issuer) American Depository Shares (Title of Class of Securities) 48669G105 (CUSIP Number) ALUMNI CAPITAL LP 80 S.W. 8TH Street Suite 2000 Miami, FL 33131 Telephone: (202) 599-5679 (Name, Address and Telephone Number o |
|
| July 10, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| July 10, 2024 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part o |
